Oncology and Hematology News and Journal Articles
Cancer Network presents exclusive coverage from the 2015 European Cancer Congress (ECC), held September 25–29 in Vienna.
A new risk assessment score more accurately reflects the probability of dying from chronic myeloid leukemia than do existing scoring systems.
A new genetic analysis found five new genetic variants that raise the risk for gliomas. One of the five was associated with a sharply increased risk for glioblastoma.
Children exposed to their mother’s cancer and cancer treatment did not appear to have cardiac, cognitive, or general developmental issues up to 36 months of age.
Treatment with intermittent imatinib is feasible among elderly CML patients who are stable responders to the drug, according to a new study.
Some patients with early-stage HR-positive breast cancer can be treated with hormone therapy alone, avoiding chemo without increasing their recurrence risk.
Significantly more women are now aware of reconstructive surgery options after mastectomies for breast cancer, following coverage of Angelina Jolie’s mastectomies in 2013.
In this video, Dr. Paz-Ares discusses a phase III study that showed that nivolumab improved survival and response rates in previously treated patients with metastatic non-squamous non-small-cell lung cancer (NSCLC).
In this video, Steven I. Sherman, MD, discusses the final overall survival analysis of the EXAM study, a randomized, placebo-controlled phase III trial of cabozantinib in medullary thyroid carcinoma patients.
In this video, Dr. El-Khoueiry discusses results from a phase I/II study that suggest the PD-1 inhibitor nivolumab is safe and effective in advanced hepatocellular carcinoma.
In this video, Dr. Tap discusses a randomized phase Ib/II trial that found that adding olaratumab to doxorubicin dramatically improved survival in patients with advanced soft-tissue sarcoma.